About: Intravenous infusion of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Intravenous infusion of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Intravenous infusion of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia
Creator	Ding, Jie Tian, Hui Wang, Weihua Yang, Yapei Tian, Suochen Wu, Tiejun Chen, Shuangfeng Li, Shuangjing Liu, Daliang Meng, Min Ren, Shaoda Zhang, Yingxin Zhou, Changhui
source	Medline; PMC
abstract	The novel coronavirus disease 2019 (COVID-19) has grown to be a global public health emergency since patients were first detected in Wuhan, China. Thus far, no specific drugs or vaccines are available to cure the patients with COVID-19 infection. The immune system and inflammation are proposed to play a central role in COVID-19 pathogenesis. Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. Intravenous infusion of MSCs has shown promising results in COVID-19 treatment. Here, we report a case of a severe COVID-19 patient treated with human umbilical cord Wharton’s jelly-derived MSCs (hWJCs) from a healthy donor in Liaocheng People’s Hospital, China, from February 24, 2020. The pulmonary function and symptoms of the patient with COVID-19 pneumonia was significantly improved in 2 days after hWJC transplantation, and recovered and discharged in 7 days after treatment. After treatment, the percentage and counts of lymphocyte subsets (CD3(+), CD4(+), and CD8(+) T cell) were increased, and the level of IL-6, TNF-α, and C-reactive protein is significantly decreased after hWJC treatment. Thus, the intravenous transplantation of hWJCs was safe and effective for the treatment of patients with COVID-19 pneumonia, especially for the patients in a critically severe condition. This report highlights the potential of hWJC infusions as an effective treatment for COVID-19 pneumonia.
has issue date	2020-05-27(xsd:dateTime)
bibo:doi	10.1186/s13287-020-01725-4
bibo:pmid	32460839
has license	cc-by
sha1sum (hex)	173ce52a9447ecdf72ff2b728379e09c8da2114c
schema:url	https://doi.org/10.1186/s13287-020-01725-4
resource representing a document's title	Intravenous infusion of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia
has PubMed Central identifier	PMC7251558
has PubMed identifier	32460839
schema:publication	Stem Cell Res Ther
resource representing a document's body	covid:173ce52a9447ecdf72ff2b728379e09c8da2114c#body_text
is schema:about of	named entity 'treated' named entity 'human' named entity 'Thus' named entity 'IMMUNE SYSTEM' named entity 'NOVEL CORONAVIRUS' named entity 'JELLY' named entity 'CURE' named entity 'SYMPTOMS' named entity 'GLOBAL' named entity 'WHARTON' named entity 'LYMPHOCYTE SUBSETS' named entity 'HERE' named entity 'FEBRUARY' named entity 'CD4' named entity 'IMPROVED' covid:arg/173ce52a9447ecdf72ff2b728379e09c8da2114c named entity 'Hospital' named entity 'vaccines' named entity 'Wuhan' named entity 'COVID-19' named entity 'immunomodulatory' named entity 'TNF-α' named entity 'Mesenchymal stem cells' named entity 'pathogenesis' named entity 'Thus' named entity 'COVID-19' named entity 'infection' named entity 'human' named entity 'China' named entity 'CD3' named entity 'MSCs' named entity 'inflammation' named entity 'vaccines' named entity 'Intravenous infusion' named entity 'pathogenesis' named entity 'lymphocyte subsets' named entity 'pneumonia' named entity 'IL-6' named entity 'safe and effective' named entity 'Liaocheng' named entity 'COVID' named entity 'COVID' named entity 'Wharton's jelly' named entity 'pneumonia' named entity 'TianLong' named entity 'clinical practice' named entity 'CD4 +' named entity 'therapeutic effects' named entity 'COVID' named entity 'San Diego' named entity 'nucleic acid' named entity 'supportive treatment' named entity 'Critically ill patients' named entity 'CRP' named entity 'Wuhan' named entity 'trypan blue' named entity 'TNF-α' named entity 'inflammatory factors' named entity 'cell death' named entity '25 March' named entity 'TNF-α' named entity 'influenza' named entity 'CD4 +' named entity 'cytokine storm' named entity 'RT-PCR' named entity 'immunoglobulin' named entity '1, 2' named entity 'full-term' named entity 'virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software